{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:43:20Z","timestamp":1787240600162,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,13]],"date-time":"2021-06-13T00:00:00Z","timestamp":1623542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,13]],"date-time":"2021-06-13T00:00:00Z","timestamp":1623542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Arena Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s40264-021-01082-y","type":"journal-article","created":{"date-parts":[[2021,6,13]],"date-time":"2021-06-13T01:02:37Z","timestamp":1623546157000},"page":"889-897","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010\u20132019"],"prefix":"10.1007","volume":"44","author":[{"given":"Juliana","family":"Setyawan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassir","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Yarur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Fridman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,13]]},"reference":[{"key":"1082_CR1","unstructured":"Venous thromboembolism (blood clots): data and statistics. Centers for Disease Control and Prevention. Updated 7 February 2020. http:\/\/cdc.gov\/ncbddd\/dvt\/data.html. Accessed 11 July 2020."},{"key":"1082_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.thromres.2015.11.033","volume":"137","author":"SD Grosse","year":"2016","unstructured":"Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res. 2016;137:3\u201310. https:\/\/doi.org\/10.1016\/j.thromres.2015.11.033.","journal-title":"Thromb Res"},{"issue":"2","key":"1082_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamacardio.2018.4537","volume":"4","author":"J Gregson","year":"2019","unstructured":"Gregson J, Kaptoge S, Bolton T, Pennells L, Willeit P, Burgess S, et al. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol. 2019;4(2):163\u201373. https:\/\/doi.org\/10.1001\/jamacardio.2018.4537.","journal-title":"JAMA Cardiol."},{"issue":"4","key":"1082_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1751-7133.2010.00148.x","volume":"16","author":"SM Dean","year":"2010","unstructured":"Dean SM, Abraham W. Venous thromboembolic disease in congestive heart failure. Congest Heart Fail. 2010;16(4):164\u20139. https:\/\/doi.org\/10.1111\/j.1751-7133.2010.00148.x.","journal-title":"Congest Heart Fail"},{"issue":"8","key":"1082_CR5","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1055\/s-0039-1692176","volume":"119","author":"JK Sejrup","year":"2019","unstructured":"Sejrup JK, B\u00f8rvik T, Grimnes G, Isaksen T, Hindberg K, Hansen JB, et al. Myocardial infarction as a transient risk factor for incident venous thromboembolism: results from a population-based case-crossover study. Thromb Haemost. 2019;119(8):1358\u201364. https:\/\/doi.org\/10.1055\/s-0039-1692176.","journal-title":"Thromb Haemost"},{"issue":"2","key":"1082_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1055\/s-0038-1661387","volume":"45","author":"JF Borjas-Howard","year":"2019","unstructured":"Borjas-Howard JF, Leeuw K, Rutgers A, Meijer K, Tichelaar V. Risk of recurrent venous thromboembolism in autoimmune diseases: a systematic review of the literature. Semin Thromb Hemost. 2019;45(2):141\u20139. https:\/\/doi.org\/10.1055\/s-0038-1661387.","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"1082_CR7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","volume":"41","author":"A Verden","year":"2018","unstructured":"Verden A, Dimbil M, Kyle R, Overstreet B, Hoffman KB. Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors. Drug Saf. 2018;41(4):357\u201361. https:\/\/doi.org\/10.1007\/s40264-017-0622-2.","journal-title":"Drug Saf"},{"issue":"2","key":"1082_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","volume":"368","author":"JJ O'Shea","year":"2013","unstructured":"O\u2019Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161\u201370. https:\/\/doi.org\/10.1056\/NEJMra1202117.","journal-title":"N Engl J Med"},{"issue":"3","key":"1082_CR9","doi-asserted-by":"publisher","first-page":"G155","DOI":"10.1152\/ajpgi.00311.2015","volume":"310","author":"S Danese","year":"2016","unstructured":"Danese S, Grisham M, Hodge J, Telliez JB. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016;310(3):G155\u201362. https:\/\/doi.org\/10.1152\/ajpgi.00311.2015.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"1082_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.idc.2020.02.014","volume":"34","author":"E Benamu","year":"2020","unstructured":"Benamu E. Infectious risks associated with biologics targeting janus kinase-signal transducer and activator of transcription signaling and complement pathway for inflammatory diseases. Infect Dis Clin North Am. 2020;34(2):271\u2013310. https:\/\/doi.org\/10.1016\/j.idc.2020.02.014.","journal-title":"Infect Dis Clin North Am"},{"issue":"1","key":"1082_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3899\/jrheum.171361","volume":"46","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol. 2019;46(1):7\u201318. https:\/\/doi.org\/10.3899\/jrheum.171361.","journal-title":"J Rheumatol"},{"issue":"5","key":"1082_CR12","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/art.40036","volume":"69","author":"JM Kremer","year":"2017","unstructured":"Kremer JM, Genovese MC, Keystone E, Taylor PC, Zuckerman SH, Ruotolo G, et al. Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase IIb study of patients with active rheumatoid arthritis. Arthritis Rheumatol. 2017;69(5):943\u201352. https:\/\/doi.org\/10.1002\/art.40036.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"1082_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234\u201343. https:\/\/doi.org\/10.1038\/nrrheum.2017.23.","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"1082_CR14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40266-020-00775-w","volume":"37","author":"S Rajasimhan","year":"2020","unstructured":"Rajasimhan S, Pamuk O, Katz JD. Safety of janus kinase inhibitors in older patients: a focus on the thromboembolic risk. Drugs Aging. 2020;37(8):551\u20138. https:\/\/doi.org\/10.1007\/s40266-020-00775-w.","journal-title":"Drugs Aging"},{"issue":"6","key":"1082_CR15","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1554-73.e12. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.001.","journal-title":"Gastroenterology"},{"issue":"8","key":"1082_CR16","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","volume":"78","author":"W Xie","year":"2019","unstructured":"Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019;78(8):1048\u201354. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214846.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1082_CR17","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/rheumatology\/keaa117","volume":"59","author":"JK Khoo","year":"2020","unstructured":"Khoo JK, Barnes H, Key S, Glaspole IN, \u00d6st\u00f6r AJ. Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis. Rheumatology (Oxford). 2020;59(9):2217\u201325. https:\/\/doi.org\/10.1093\/rheumatology\/keaa117.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"1082_CR18","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1093\/ibd\/izaa002","volume":"26","author":"JD McCurdy","year":"2020","unstructured":"McCurdy JD, Kuenzig ME, Smith G, Spruin S, Murthy SK, Carrier M, et al. Risk of venous thromboembolism after hospital discharge in patients with inflammatory bowel disease: a population-based study. Inflamm Bowel Dis. 2020;26(11):1761\u20138. https:\/\/doi.org\/10.1093\/ibd\/izaa002.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"1082_CR19","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3748\/wjg.v26.i12.1231","volume":"26","author":"K Cheng","year":"2020","unstructured":"Cheng K, Faye AS. Venous thromboembolism in inflammatory bowel disease. World J Gastroenterol. 2020;26(12):1231\u201341. https:\/\/doi.org\/10.3748\/wjg.v26.i12.1231.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"1082_CR20","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1136\/annrheumdis-2013-203380","volume":"73","author":"WS Chung","year":"2014","unstructured":"Chung WS, Peng CL, Lin CL, Chang YJ, Chen YF, Chiang JY, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis. 2014;73(10):1774\u201380. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203380.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1082_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10067-014-2492-7","volume":"33","author":"P Ungprasert","year":"2014","unstructured":"Ungprasert P, Srivali N, Spanuchart I, Thongprayoon C, Knight EL. Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2014;33(3):297\u2013304. https:\/\/doi.org\/10.1007\/s10067-014-2492-7.","journal-title":"Clin Rheumatol"},{"key":"1082_CR22","unstructured":"International Council for Harmonisation (ICH). 2019. https:\/\/www.ich.org\/page\/meddra."},{"issue":"11","key":"1082_CR23","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","volume":"79","author":"P Mease","year":"2020","unstructured":"Mease P, Charles-Schoeman C, Cohen S, Fallon L, Woolcott J, Yun H, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020;79(11):1400\u201313. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216761.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1082_CR24","doi-asserted-by":"publisher","first-page":"102390","DOI":"10.1016\/j.autrev.2019.102390","volume":"18","author":"Y Jamilloux","year":"2019","unstructured":"Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, S\u00e8ve P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2019;18(11):102390. https:\/\/doi.org\/10.1016\/j.autrev.2019.102390.","journal-title":"Autoimmun Rev"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01082-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01082-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01082-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T11:37:38Z","timestamp":1626262658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01082-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,13]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1082"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01082-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,13]]},"assertion":[{"value":"18 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by Arena Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Juliana Setyawan is an employee of and owns stock in Arena Pharmaceuticals. Nassir Azimi, Vibeke Strand, Andres Yarur, and Moshe Fridman have received consulting fees from Arena Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data are available on the FAERS database.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the writing and editing of this paper. JS and MF designed the study, and MF performed all analyses. All authors contributed to the interpretation of the results, and read and approved the final version submitted for publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}